Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

UFS hosts the 2017 SAIMS Conference
2017-09-21

Description: SAIMS confrence Tags: SAIMS, Kopano Nokeng, conference, research, Prof Francis Petersen, business, Kovsies, St Dairy, Mushrooms House 

The hosts of the 2017 SAIMS conference:
Dr Jacques Nel
(UFS:Business Management), Prof Francis Petersen
(UFS Rector and Vice-Chancellor),
Dr Werner Vermeulen (HOD of UFS: Business Management),
Dr Habofanwe Koloba (UFS: Business Management),
and Prof Hendri Kroukamp
(UFS: Dean of Economic and Management Sciences).
Photo: Supplied



The University of the Free State’s (UFS) Department of Business Management recently hosted the 29th South African Institute of Management Scientists (SAIMS) conference at Kopano Nokeng in Bloemfontein. This year’s theme, ‘Management Research: Science Serving Practice’ focused on the importance of sharing our results and making it relevant and usable to different communities.

Prof Petersen motivates researchers to become part of the business cycle 
On the first day of the conference, the Rector and Vice-Chancellor of the UFS, Prof Francis Peterson, welcomed 148 delegates from 18 different institutions (academic and professional) to the City of Roses. He motivated them to keep on doing highly scholarly research by being part of the business cycles.

Prof Adré Schreuder, founder of Consulta (Pty) Ltd, was the keynote speaker of the conference. He highlighted four personas needed to further enhance and develop the science-practice alignment in market research and business. “The first skills persona is called a Social Media Maven, which is in line with the rapid growth of social media networks and the growing need for social media analytics. Then there is the Data Synthesiser that supports the growth trend in Big Data and Advanced analytics, which are both driven by technological innovation and the enormous volume of available data. The third one is Marketing Strategist, which has strong representation in brand and advertising research in our industry. Lastly, we have the ‘Business Consultant’ which aligns with the industry trends towards deeper insights and consultative skills required to move beyond mere reporting, but rather getting involved in the design and implementation of recommendations.”

Conference to collaborate academics and business
Dr Werner Vermeulen, SAIMS 2017 Conference Chair, says, “This conference will underpin the need for collaboration and cooperation of individuals from the academic environment and the business world itself.” He says the conference will also provide a wonderful forum to refresh knowledge and explore contemporary trends and future-based business research.
 
Delegates were also given the opportunity to dress up to the carnival theme and were entertained by a fire dancer and magician. They had the honour of indulging in two Kovsie-produced food products, the St Dairy organic cheese and exotic mushrooms by Mushroom House

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept